Zydus Cadila has announced that the WHO INN (International Nonproprietary Name) committee has granted the name Desidustat to its Phase II anemia candidate, ZYAN1. The INN system aims to provide healthcare professionals with a unique and universal designated name for each pharmaceutical substance.
Desidustat is an oral small molecule that has been designed to inhibit hypoxia-inducible factor prolyl hydroxylase, and thereby increase the natural production of hemoglobin and RBCs in anemic patients. The molecule has been shown to improve iron mobilization and has the potential to reduce or eliminate the need for iron supplementation.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines.
